Atypical hemolytic uremic syndrome (aHUS) Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Atypical hemolytic uremic syndrome (aHUS) Pipeline Analysis report covers 10 drugs currently in different phases of development. Atypical hemolytic-uremic syndrome is a rare renal disease characterised by abnormal clotting: haemolytic anaemia, thrombocytopenia, and kidney failure. There is a formation of blood clots blood vessels in the kidneys which restricts the blood flow to kidney. The disease may be inherited or acquired.
The report provides Atypical hemolytic uremic syndrome (aHUS) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Alexion Pharmaceuticals, Omeros Corporation among others.
By Molecule Type
By Route of Administration